Thursday, April 13, 2023 9:08:16 PM
April 13 2023 - 08:45PM
GlobeNewswire Inc
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech’s Biologics License Application (BLA) for AVT02, a high-concentration biosimilar candidate for Humira® (adalimumab). The CRL noted that certain deficiencies, which were conveyed following the FDA’s reinspection of the company’s Reykjavik facility that concluded on March 17, 2023, must be satisfactorily resolved before the application can be approved. No other deficiencies in the application were noted by the FDA. Alvotech provided the FDA comprehensive responses to the inspection observations on April 3, 2023, and is awaiting communication from the agency assessing those responses.
Alvotech’s second BLA for AVT02, which contains data to support approval as a biosimilar and additional information supporting potential interchangeability designation – remains under review by the FDA, with a Biosimilar User Fee Amendment (BsUFA) goal date of June 28, 2023. Satisfactory outcome of the facility reinspection remains the key requirement for approval.
“We look forward to working with the FDA to resolve any outstanding issues identified in the reinspection,” said Robert Wessman, Chairman and CEO of Alvotech. “We are committed to manufacturing AVT02 for patients in the United States, especially a potentially differentiated Humira biosimilar that provides a high-concentration formulation and is interchangeable.”
About AVT02
AVT02 is a monoclonal antibody and has been approved as a biosimilar to Humira® (adalimumab) in the 27 EU member countries, Norway, Lichtenstein, Iceland, the UK, Switzerland, Canada, Australia and Saudi Arabia. It is currently marketed in sixteen countries in Europe and in Canada. Dossiers are under review in multiple countries, including in the United States.
About Alvotech
Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech’s current pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.
Recent ALVO News
- Alvotech Announces Participation at BofA Securities Healthcare Conference 2024 • GlobeNewswire Inc. • 05/02/2024 11:15:00 AM
- U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab) • Business Wire • 04/30/2024 08:00:00 AM
- U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab) • GlobeNewswire Inc. • 04/30/2024 08:00:00 AM
- Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab) • GlobeNewswire Inc. • 04/24/2024 08:00:00 AM
- Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab) • GlobeNewswire Inc. • 04/19/2024 10:10:00 AM
- Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) • Business Wire • 04/16/2024 09:43:00 PM
- Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) • GlobeNewswire Inc. • 04/16/2024 09:30:00 PM
- Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024 • GlobeNewswire Inc. • 04/03/2024 11:41:03 AM
- Alvotech Announces Increase in Number of Own Shares • GlobeNewswire Inc. • 03/22/2024 08:15:00 PM
- Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update • GlobeNewswire Inc. • 03/20/2024 08:15:00 PM
- U.S. Index Futures Trade Sideways Amid Anticipation of Fed’s Policy Update; Oil Prices Dip • IH Market News • 03/20/2024 11:17:32 AM
- Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET • GlobeNewswire Inc. • 03/05/2024 09:00:00 PM
- Alvotech Appoints Interim Chief Quality Officer • GlobeNewswire Inc. • 02/29/2024 09:05:00 PM
- Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share • GlobeNewswire Inc. • 02/26/2024 09:25:00 AM
- Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira® • GlobeNewswire Inc. • 02/24/2024 01:15:09 AM
- Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira® • Business Wire • 02/24/2024 01:15:00 AM
- Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab) • GlobeNewswire Inc. • 02/15/2024 11:30:00 AM
- Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva® • GlobeNewswire Inc. • 01/29/2024 09:00:00 AM
- Alvotech Shares Climb After FDA Concludes Facility Inspection • Dow Jones News • 01/19/2024 05:31:00 PM
- Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04 • GlobeNewswire Inc. • 01/19/2024 04:30:00 PM
- STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara • GlobeNewswire Inc. • 01/10/2024 08:30:00 AM
- Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept) • GlobeNewswire Inc. • 01/03/2024 08:30:00 AM
- Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria® • GlobeNewswire Inc. • 11/29/2023 09:00:00 AM
- Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update • GlobeNewswire Inc. • 11/28/2023 09:15:00 PM
- Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Host Business Update Conference Call on November 29, 2023, at 8:00 am ET • GlobeNewswire Inc. • 11/21/2023 01:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM